GTS Securities’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-24,770
Closed -$3.19M 2791
2024
Q3
$3.19M Sell
24,770
-26,600
-52% -$3.47M 0.01% 1226
2024
Q2
$5.83M Buy
51,370
+8,850
+21% +$947K 0.01% 767
2024
Q1
$5.64M Sell
42,520
-4,480
-10% -$585K 0.01% 788
2023
Q4
$5.73M Buy
47,000
+28,385
+152% +$2.17M 0.01% 904
2023
Q3
$1.42M Buy
+18,615
New +$1.91M ﹤0.01% 1755

Other funds holding LABU

GTS Securities's LABU Position: Q1 2026 in Review

GTS Securities sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q1 2026, closing a stake of 10,466 shares — an estimated $1.67M sold.

GTS Securities first reported a position in LABU in Q2 2023 and held it in 9 quarters. The position peaked at $6.09M in Q3 2024. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

  • GTS Securities reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q1 2026 after selling out during the quarter.
  • GTS Securities sold 10,466 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2026, an estimated $1.67M.
  • GTS Securities first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q2 2023 and held it in 9 quarters.
  • GTS Securities's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $6.09M in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.